Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 1, 2013, Pages 60-65

  Halim, Amal ^a   Abotouk, Niveen ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Metastatic bladder cancer; Paclitaxel; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REPEATED DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA OF THE BLADDER; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84874108659     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01554.x     Document Type: Article

References (45)

1. Vaughn DJ. Paclitaxel and carboplatin in bladder cancer: recent developments. Eur J Cancer 2000; 36: 7-12.
2. Loehrer PJ Sr, Einhorn LH, Elson PJ etal. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
3. Von der Maase H, Hansen SW, Roberts JT etal. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multiinstitutional, phase III study. J Clin Oncol 2000; 18: 3068-3077.
4. Uhm JE, Lim HY, Kim WS etal. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 2007; 9: 18-22.
5. Tsavaris N, Kosmas C, Skopelitis H etal. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study. J Chemother 2005; 17: 441-448.
6. Miller AB, Hoagtraton B, Staguet M etal. Reporting results of cancer treatment. Cancer 1981; 47: 207-212.
7. Trotti A, Coleras AD, Setser A etal. CTCAE v 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
8. Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist 2005; 10: 792-798.
9. McCaffrey JA, Hilton S, Mazumdar M etal. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997; 15: 1853-1857.
10. Papamichael D, Gallagher CJ, Oliver RT etal. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75: 606-607.
11. Pronzato P, Vigani A, Pensa F etal. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997; 20: 519-521.
12. Witte RS, Eison P, Bono B etal. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15: 589-593.
13. Lorusso V, Pollera CF, Antimi M etal. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998; 34: 1208-1212.
14. Witte RS, Manola J, Burch PA etal. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998; 16: 191-195.
15. Gebbia V, Testa A, Borsellino N etal. Single agent 2′2′ difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999; 150: 11-15.
16. Albers P, Siener R, Hartlein M etal. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma-prognostic factors for response and improvement of quality of life. Onkologie 2002; 25: 47-52.
17. Vaughn DJ, Broome CM, Hussain M etal. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-940.
18. Sweeney CJ, Roth BJ, Kabbinover FF etal. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24: 3451-3457.
19. Culine S, Theodore C, De Santis M etal. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94: 1395-1401.
20. Akaza H, Naito S, Usami M etal. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin containing therapy: a Japanese experience. Jpn J Clin Oncol 2007; 37: 201-206.
21. Galsky MD, Mironov S, Iasonos M etal. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265-270.
22. Bellmunt Molins J, von der Maase H, Theodore C etal. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009; 27: 4454-4461.
23. Vaughn DJ, Srinivas S, Stadler WM etal. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase II study. Cancer 2009; 115: 4110-4117.
24. Yafi FA, North S, Kassouf W. First and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011; 18: 25-34.
25. Logothetis CJ, Hossan E, Recondo G etal. 5-fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 1994; 14: 1265-1269.
26. Tu SM, Hossan E, Amato R etal. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 1995; 154: 1719-1722.
27. Sweeney CJ, Williams SD, Finch DE etal. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999; 86: 514-518.
28. De Mulder PH, Theodore C, Sella A etal. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second -line treatment of advanced transitional cell cancer of the urothelial tract. Ann Oncol 2000; 11: 1391-1394.
29. Krege S, Rembrink V, Borgermann C, Otto T etal. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 2001; 165: 67-71.
30. Meluch AA, Greco FA, Burris HA etal. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19: 3018-3024.
31. Sternberg CN, Calabro F, Pizzocaro G etal. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-2998.
32. Bellmunt J, Cos J, Cleries R etal. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002; 20: 673-685.
33. Pagliaro LC, Millikan RE, Tu SM etal. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 2002; 20: 2965-2970.
34. Kaufman DS, Carducci MA, Kuzel TM etal. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004; 22: 393-397.
35. Vaishampayan UN, Faulkner JR, Small EJ etal. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma. Cancer 2005; 104: 1627-1632.
36. Fechner G, Siener R, Reimann M etal. Randomized phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 2006; 60: 27-31.
37. Takahashi T, Higashi S, Nishiyama H etal. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol 2006; 36: 104-108.
38. Lin CC, Hsu CH, Huang CY etal. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 2007; 18: 487-491.
39. Kanai K, Kikuchi E, Ohigashi T etal. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol 2008; 13: 510-514.
40. Suyama T, Ueda T, Fukasawa S etal. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 2009; 39: 244-250.
41. Zhang GZ, Jiao SC, Meng ZT. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 2010; 27: 29-38.
42. Bellmont J, Choueiri TK, Fougeray R etal. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-1855.
43. Gelderblom H, Verweij J, Nooter K etal. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598.
44. Authier N, Gillet JP, Fialip J etal. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001; 3: 301-306.
45. Gradishar WJ, Tjulandin S, Davidson N etal. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.